Attovia Therapeutics (ATTO) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on immune-mediated diseases using the ATTOBODY biologics platform.

• Lead candidates target validated pathways in dermatology and inflammatory diseases.

• Pipeline includes ATTO-1310 (anti-IL-31), ATTO-2306 (bispecific anti-IL-13/IL-31), and ATTO-1091 (trispecific for TL1A, IL-23, integrin α4β7).

• All candidates discovered internally using a high-throughput, modular platform licensed from Alamar Biosciences.

• Strategy includes expanding pipeline, pursuing precision immunology, and leveraging collaborations.

Financial performance and metrics

• No product revenue to date; revenue of $1.4M in 2025 from collaboration agreements.

• Net losses: $39.8M (2024), $60.6M (2025), $18.7M (Q1 2026); accumulated deficit of $129.7M as of March 31, 2026.

• Cash, cash equivalents, and marketable securities: $132.6M as of March 31, 2026.

• Raised $255.8M in equity financing since inception.

Use of proceeds and capital allocation

• Net proceeds from IPO, together with existing cash, to fund clinical development of ATTO-1310, ATTO-2306, and ATTO-1091, as well as pipeline R&D, working capital, and general corporate purposes.

• Proceeds will not be sufficient to fund candidates through regulatory approval; additional capital will be required.